HTG Molecular Diagnostics, Inc. (NASDAQ:HTGM) major shareholder Holdings A/S Novo sold 47,162 shares of the firm’s stock in a transaction on Wednesday, August 23rd. The shares were sold at an average price of $2.02, for a total transaction of $95,267.24. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Major shareholders that own at least 10% of a company’s stock are required to disclose their transactions with the SEC.

Holdings A/S Novo also recently made the following trade(s):

  • On Thursday, August 24th, Holdings A/S Novo sold 382,437 shares of HTG Molecular Diagnostics stock. The shares were sold at an average price of $1.91, for a total transaction of $730,454.67.
  • On Friday, August 25th, Holdings A/S Novo sold 1,149,813 shares of HTG Molecular Diagnostics stock. The stock was sold at an average price of $1.81, for a total transaction of $2,081,161.53.
  • On Tuesday, August 22nd, Holdings A/S Novo sold 80,586 shares of HTG Molecular Diagnostics stock. The stock was sold at an average price of $2.07, for a total transaction of $166,813.02.

Shares of HTG Molecular Diagnostics, Inc. (NASDAQ HTGM) opened at 1.90 on Monday. The company’s 50-day moving average is $2.27 and its 200 day moving average is $3.38. HTG Molecular Diagnostics, Inc. has a 1-year low of $1.20 and a 1-year high of $13.25. The stock’s market cap is $21.75 million.

HTG Molecular Diagnostics (NASDAQ:HTGM) last announced its earnings results on Tuesday, August 8th. The medical research company reported ($0.60) earnings per share (EPS) for the quarter, meeting the Zacks’ consensus estimate of ($0.60). The company had revenue of $1.76 million during the quarter, compared to analysts’ expectations of $1.80 million. HTG Molecular Diagnostics had a negative net margin of 432.74% and a negative return on equity of 1,538.49%. Equities research analysts anticipate that HTG Molecular Diagnostics, Inc. will post ($2.29) EPS for the current year.

COPYRIGHT VIOLATION NOTICE: “HTG Molecular Diagnostics, Inc. (HTGM) Major Shareholder Sells $95,267.24 in Stock” was originally reported by TheOlympiaReport and is the sole property of of TheOlympiaReport. If you are reading this news story on another publication, it was stolen and reposted in violation of United States & international copyright laws. The original version of this news story can be accessed at https://theolympiareport.com/2017/08/28/htg-molecular-diagnostics-inc-htgm-major-shareholder-sells-95267-24-in-stock.html.

Several equities research analysts recently issued reports on HTGM shares. Zacks Investment Research raised shares of HTG Molecular Diagnostics from a “hold” rating to a “buy” rating and set a $4.50 price target on the stock in a research note on Thursday, May 11th. ValuEngine raised shares of HTG Molecular Diagnostics from a “strong sell” rating to a “sell” rating in a research note on Saturday, August 12th. Rodman & Renshaw lifted their price target on shares of HTG Molecular Diagnostics from $4.50 to $6.00 and gave the stock a “buy” rating in a research note on Tuesday, May 16th. Finally, HC Wainwright set a $6.00 price target on shares of HTG Molecular Diagnostics and gave the stock a “buy” rating in a research note on Wednesday, August 9th. Two research analysts have rated the stock with a sell rating, one has issued a hold rating and two have assigned a buy rating to the stock. The stock currently has an average rating of “Hold” and a consensus price target of $5.75.

Several large investors have recently made changes to their positions in HTGM. Renaissance Technologies LLC boosted its stake in shares of HTG Molecular Diagnostics by 32.3% in the fourth quarter. Renaissance Technologies LLC now owns 58,200 shares of the medical research company’s stock worth $130,000 after buying an additional 14,206 shares during the last quarter. UBS Group AG acquired a new stake in shares of HTG Molecular Diagnostics during the first quarter worth about $137,000. Two Sigma Securities LLC acquired a new stake in shares of HTG Molecular Diagnostics during the first quarter worth about $150,000. Granahan Investment Management Inc. MA acquired a new stake in shares of HTG Molecular Diagnostics during the first quarter worth about $228,000. Finally, Vanguard Group Inc. boosted its stake in shares of HTG Molecular Diagnostics by 38.9% in the second quarter. Vanguard Group Inc. now owns 135,234 shares of the medical research company’s stock worth $359,000 after buying an additional 37,841 shares during the last quarter. 21.67% of the stock is owned by institutional investors.

HTG Molecular Diagnostics Company Profile

HTG Molecular Diagnostics, Inc is a commercial-stage company that develops and markets a technology platform to facilitate the routine use of complex molecular profiling. The Company’s HTG Edge and HTG EdgeSeq platforms, consisting of instrumentation, consumables and software analytics, are used in sample profiling applications, including tumor profiling, molecular diagnostic testing and biomarker development.

Receive News & Ratings for HTG Molecular Diagnostics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for HTG Molecular Diagnostics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.